Clinical Trial Update: Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Novartis-sponsored study evaluating pharmacodynamic effects of VAY736 in patients with Primary Sjögren's Syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• VAY736

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Sjögren's Syndrome | Phase 1, Phase 2 | Status: WITHDRAWN